{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:15Z","timestamp":1792773375666,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,9]]},"abstract":"<jats:p>\n                    The clinical management of patients with both coronavirus disease 2019 (COVID-19) and breast cancer remains a complex and unresolved issue that despite extensive discussion has not reached a consensus. In contemporary literature, the association between COVID-19 and HER2-positive breast cancer has received minimal attention. Genetic instruments for severe acute respiratory syndrome coronavirus 2 infection (N\u2005=\u20052,597,856), hospitalized COVID-19 (N\u2005=\u20052,095,324), and critically ill COVID-19 (N\u2005=\u20051,086,211) were obtained from the COVID-19 Host Genetics Initiative genome-wide association study (GWAS) meta-analysis. A total of 103,530 HER2-positive breast cancer cases from GWAS were enrolled in our study. The summary GWAS statistics of 731 immune cells (N\u2005=\u20053757) were obtained from the MRCEU open database. Causal associations were evaluated by applying Mendelian randomization (MR) including inverse variance weighting, MR-Egger regression, and weighted-median analysis. Sensitivity analyses were employed, including Cochran\n                    <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                    test, MR-Egger intercept test, MR Pleiotropy Residual Sum and Outlier, and leave-one-out analysis, to examine the robustness of these findings. Genetic liability to critically ill COVID-19 was significantly causally associated with the increased risk of HER2-positive breast cancer (odds ratios\u2005=\u20051.086, 95% confidence intervals\u2005=\u20051.015\u20131.162,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.016). No causal associations between severe acute respiratory syndrome coronavirus 2 infection or hospitalized COVID-19 and HER2-positive breast cancer were observed. Additionally, genetic liabilities to critically ill COVID-19 were significantly positively associated with 9 immune cells. IgD- CD27- AC and CD27 on IgD+ CD38- unsw mem (memory B cells) were identified as potential mediators of the causal relationship between critically ill COVID-19 and HER2-positive breast cancer. Genetic liability to critically ill COVID-19 is associated with an increased risk of HER2-positive breast cancer possibly through the immune pathway. Future studies are essential to elucidate the mechanisms underlying this causal relationship, aiming to develop therapeutic strategies to mitigate the immune cell-mediated impact on HER2-positive breast cancer risk.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042372","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T21:00:28Z","timestamp":1747083628000},"page":"e42372","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Genetic liability to critically ill COVID-19 increased risk of HER2-positive breast cancer through the immune pathway: A Mendelian randomization study"],"prefix":"10.1097","volume":"104","author":[{"given":"Jianfeng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Toxicology II, Hunan Prevention and Treatment Institute for Occupational Diseases (Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China), Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Toxicology II, Hunan Prevention and Treatment Institute for Occupational Diseases (Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China), Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Occupational Lung Diseases II, Hunan Institute of Occupational Disease Prevention, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Toxicology II, Hunan Prevention and Treatment Institute for Occupational Diseases (Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China), Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Toxicology II, Hunan Prevention and Treatment Institute for Occupational Diseases (Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China), Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2510-725X","authenticated-orcid":false,"given":"Xiaochuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Toxicology II, Hunan Prevention and Treatment Institute for Occupational Diseases (Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China), Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261023","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s15010-021-01603-y","article-title":"Characteristics of viral pneumonia in the COVID-19 era: an update.","volume":"49","author":"Pagliano","year":"2021","journal-title":"Infection"},{"key":"R2-20261023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jhep.2020.09.031","article-title":"COVID-19: Discovery, diagnostics and drug development.","volume":"74","author":"Asselah","year":"2021","journal-title":"J Hepatol"},{"key":"R3-20261023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10654-022-00962-6","article-title":"Characterising patterns of COVID-19 and long COVID symptoms: evidence from nine UK longitudinal studies.","volume":"38","author":"Bowyer","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"R4-20261023","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.ctrv.2020.102041","article-title":"Cancer and COVID-19: Unmasking their ties.","volume":"88","author":"Addeo","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R5-20261023","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R6-20261023","article-title":"Managing cancer care during the COVID-19 pandemic: Agility and collaboration toward a common goal","author":"Ueda","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-20261023","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: An up-to-date review and future perspectives.","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R8-20261023","doi-asserted-by":"crossref","first-page":"e21487","DOI":"10.1097\/MD.0000000000021487","article-title":"Prognosis of COVID-19 in patients with breast cancer: a protocol for systematic review and meta-analysis.","volume":"99","author":"Sheng","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R9-20261023","first-page":"100261","article-title":"Real-world outcomes in thoracic cancer patients with severe acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience.","volume":"25","author":"Cui","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"R10-20261023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13058-020-01293-8","article-title":"COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.","volume":"22","author":"Vuagnat","year":"2020","journal-title":"Breast Cancer Res"},{"key":"R11-20261023","first-page":"575","article-title":"Cross Talk between COVID-19 and breast cancer.","volume":"21","author":"Parmar","year":"2021","journal-title":"Curr Cancer Drug Targets"},{"key":"R12-20261023","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1389201023666220421133311","article-title":"Impacts of COVID-19 in breast cancer: from molecular mechanism to the treatment approach.","volume":"24","author":"Stipp","year":"2023","journal-title":"Curr Pharm Biotechnol"},{"key":"R13-20261023","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.21037\/gs-23-447","article-title":"Neoadjuvant T-DM1 for HER2-positive breast cancer used as a bridging strategy during COVID-19 pandemic: lessons learned-a case series.","volume":"13","author":"Choppa","year":"2024","journal-title":"Gland Surg"},{"key":"R14-20261023","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR Statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R15-20261023","doi-asserted-by":"crossref","first-page":"123411","DOI":"10.1016\/j.wneu.2024.10.140","article-title":"Causal relationship between immune cells and hypopituitarism: bidirectional mendelian randomization study.","volume":"194","author":"Zhao","year":"2025","journal-title":"World Neurosurg"},{"key":"R16-20261023","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.1038\/s41598-025-95546-1","article-title":"Deciphering genetic causality between plasma BDNF and 91 circulating inflammatory proteins through bidirectional mendelian randomization.","volume":"15","author":"Sun","year":"2025","journal-title":"Sci Rep"},{"key":"R17-20261023","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R18-20261023","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"R19-20261023","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamaoncol.2021.0884","article-title":"Association of cancer screening deficit in the United States With the COVID-19 Pandemic.","volume":"7","author":"Chen","year":"2021","journal-title":"JAMA Oncol"},{"key":"R20-20261023","first-page":"100321","article-title":"High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis.","volume":"27","author":"Nair","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"R21-20261023","doi-asserted-by":"crossref","first-page":"570130","DOI":"10.3389\/fonc.2020.570130","article-title":"Characteristics and outcomes of 35 breast cancer patients infected with COVID-19.","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"R22-20261023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcrc.2021.08.007","article-title":"Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): a two-center, retrospective cohort study.","volume":"66","author":"Al Sulaiman","year":"2021","journal-title":"J Crit Care"},{"key":"R23-20261023","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ccell.2020.09.019","article-title":"Cytokine Storms in Cancer and COVID-19.","volume":"38","author":"Turnquist","year":"2020","journal-title":"Cancer Cell"},{"key":"R24-20261023","doi-asserted-by":"crossref","first-page":"1161067","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.","volume":"14","author":"Carlini","year":"2023","journal-title":"Front Immunol"},{"key":"R25-20261023","doi-asserted-by":"crossref","first-page":"108943","DOI":"10.1016\/j.celrep.2021.108943","article-title":"Cell-type-specific immune dysregulation in severely ill COVID-19 patients.","volume":"34","author":"Yao","year":"2021","journal-title":"Cell Rep"},{"key":"R26-20261023","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/biomedicines10020300","article-title":"Cooperation between angiogenesis, vasculogenesis, chemotaxis, and coagulation in breast cancer metastases development: pathophysiological point of view.","volume":"10","author":"Zarychta","year":"2022","journal-title":"Biomedicines"},{"key":"R27-20261023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-407190-2.00003-4","article-title":"Role of oxidative stress and the microenvironment in breast cancer development and progression.","volume":"119","author":"Jezierska-Drutel","year":"2013","journal-title":"Adv Cancer Res"},{"key":"R28-20261023","doi-asserted-by":"crossref","first-page":"100666","DOI":"10.1016\/j.bj.2023.100666","article-title":"Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.","volume":"47","author":"Reinig","year":"2024","journal-title":"Biomed J"},{"key":"R29-20261023","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science.","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"R30-20261023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3892\/ijo.2020.5159","article-title":"Immune-checkpoint inhibitors from cancer to COVID\u201119: a promising avenue for the treatment of patients with COVID\u201119 (Review).","volume":"58","author":"Vivarelli","year":"2021","journal-title":"Int J Oncol"},{"key":"R31-20261023","doi-asserted-by":"crossref","first-page":"e000255","DOI":"10.1136\/esmoopen-2017-000255","article-title":"Targeting immune checkpoints in breast cancer: an update of early results.","volume":"2","author":"Solinas","year":"2017","journal-title":"ESMO Open"},{"key":"R32-20261023","doi-asserted-by":"crossref","first-page":"593","DOI":"10.21037\/atm.2019.09.68","article-title":"Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy.","volume":"7","author":"Deshmukh","year":"2019","journal-title":"Ann Transl Med"},{"key":"R33-20261023","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ajpath.2023.02.005","article-title":"Lung remodeling regions in long-term coronavirus disease 2019 feature basal epithelial cell reprogramming.","volume":"193","author":"Wu","year":"2023","journal-title":"Am J Pathol"},{"key":"R34-20261023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13058-020-01360-0","article-title":"COVID-19: a potential driver of immune-mediated breast cancer recurrence?","volume":"22","author":"Francescangeli","year":"2020","journal-title":"Breast Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:00:43Z","timestamp":1792767643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042372","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}